

# Enhanced antimalarial effects of chloroquine by aqueous *Vernonia amygdalina* leaf extract in mice infected with chloroquine resistant and sensitive *Plasmodium berghei* strains

Iwalokun, BA

Department of Biochemistry, Lagos State University, Ojo, P.M.B 1087, Apapa – Lagos, Nigeria, E-mail: bamwal@yahoo

## Abstract

**Background:** The emergence and spread of *Plasmodium falciparum* with resistance to chloroquine (CQ), the safest and cheapest antimalarial drug coupled with the increasing cost of alternative drugs especially in developing countries have necessitated the need to optimize antimalarial actions of plant extracts and restore chloroquine efficacy.

**Objective:** The present study determines the ability of *Vernonia amygdalina* leaf extract to enhance the prophylactic and therapeutic efficacy of chloroquine against *Plasmodium berghei* malaria in mice.

**Methods:** Chloroquine sensitive (*P.berghei*<sup>S</sup>) and resistant (*P.berghei*<sup>R</sup>) ANKA clones of *Plasmodium berghei* maintained by serial passage in mice were used to develop respective experimental rodent malaria models based on intraperitoneal injection of 10<sup>6</sup> parasitized erythrocyte suspension in PBS (pH 7.2) and subsequent development of parasitaemia. These models were then used to investigate the prophylactic enhancement of chloroquine (CQ) at 5 mg/kg via combination with selected doses (31.25, 62.5, 125mg/kgbw) of *Vernonia amygdalina* leaf extracts using a 4-day suppression test. Effect of these combinations on the therapeutic efficacy of CQ at 30mg/kg over 3 days were evaluated. Treatment outcomes including parasite clearance (PCT) and recrudescence time (RT) were compared with CQ-chlorpheniramine combination. The acute toxicity of the extract-CQ combinations was also determined enzymatically.

**Results:** Prophylactically, chloroquine (5mg/kg) in combination with vernonia extracts achieved a dose-dependent (57.2 – 72.7%) suppression of parasitaemia due to CQ sensitive and resistant *P.berghei* strains in the experimental animals. Therapeutically, chloroquine (30mg/kg for 3 days) combined with vernonia to dose-dependently shorten the parasite clearance times (2.6 – 4.4 vs. 4.8 days;  $P < 0.05$  for CQ-V62.5/125 combination), prolong the recrudescence times (8.9 – 18.9 vs. 7.2 days;  $P < 0.05$ ) and improve day 14 cure rate (66.7 – 100 vs. 58.3%) in the treated *P.berghei*<sup>S</sup> infected mice compared to CQ monotherapy. Whereas CQ monotherapy failed, resolution of parasitaemia due to the CQ resistant parasite with day 14 cure rates of 25 – 100% were also observed with these combinations. In therapeutic terms, the potencies of CQ-V125 combination were comparable to those of CQ-chlorpheniramine (0.25mg/kg, 12hourly, 7 days) in the infected animals. Toxicity testing indicates that these combinations elicited mild to – moderate increases in the liver enzymes measured when administered orally to mice for 7 days.

**Conclusion:** This study indicates that *Vernonia amygdalina* leaf extract dose – dependently restore the efficacy of CQ against CQ resistance *P.berghei* malaria in mice.

**Key words:** *Plasmodium berghei* infection, chloroquine resistance, *vernonia amygdalina* extracts, chloroquine – vernonia combination, Toxicity.

*African Health Sciences* 2008; 8(1): 25-35

## Introduction

Malaria remains the greatest cause of hospitalization and deaths among the parasitic infections that afflict man<sup>[1]</sup>. Over 40% of the world's population are at risk of malaria and active clinical cases due to *Plasmodium falciparum* parasitaemia is estimated to be 300 - 500 million annually with over 90% occurrence mostly in children and primigravidae in Sub-Saharan African. 1 - 3% of these cases result in 1.5-2.7 million deaths due to anaemia, cerebral malaria and acidotic complications<sup>2,3</sup>.

Chemotherapy remains the kernel of malaria control and the previously efficacious chloroquine has substantially failed as a prophylactic and therapeutic antimalarial in many endemic countries of Africa, Asia and South America due to a corresponding spread of chloroquine resistant *P. falciparum* strains with mutant alleles for chloroquine resistance transporter proteins

(pfCRT76) and multidrug resistance glycoprotein-1 (pfmdr-1Y86)<sup>4,5</sup>. Consequently, the diminished potency of chloroquine above the 25% failure in many of the endemic countries including Nigeria, have paved way for the use of other antimalarial drugs in the armamentarium. Unfortunately, these alternative antimalarial drugs including sulphadoxine-pyrimethamine, mefloquine and halofantrine have also been observed to have their efficacy comprised by resistance developed by *P. falciparum* against them<sup>6,7</sup>. Furthermore, these drugs are not only costlier than chloroquine but also parade heterogenous levels of toxicity and may invoke poor compliance in patients<sup>8</sup>.

Artemisinins in combination with other antimalarials with distinct mode of actions remain the only regimens for which clinical failures have not been documented<sup>9</sup>. However, most of these regimens are administered in loose doses and are currently having

difficulty in implementation especially in rural areas of developing countries due to affordability and accessibility constraints<sup>10,11</sup>.

Surprisingly, chloroquine remains the regimen of choice against malaria in pregnancy due to its enormous safety and cheapness, which remains insurmountable by other antimalarial alternatives<sup>12</sup>. Taken together, the above findings have provided a justifiable evidence and need to develop strategies of restoring chloroquine efficacy and prolong its clinical utility as an antimalarial drug. In the last twenty years, these strategies have employed pharmaceutical drugs masquerading as antidepressants (e.g. fluoxetine and desipramine), antihistamines (e.g. promethazine and chlorpheniramine), calcium channels blockers (e.g. verapamil and nifedipine) and antipsychotics (e.g. chlorpromazine) to reverse chloroquine resistance by *P. falciparum* *in vitro* and *in vivo* in rodent and apes malaria models<sup>13, 14, 15, 16, 17</sup>. In these studies, positive outcomes include reduced 50% inhibitory concentrations of chloroquine (IC<sub>50s</sub>), increased chloroquine uptake and chloroquine ferriprotoporphyrin IX binding<sup>14, 17</sup>. However, the replication of these therapeutic benefits in human malaria has been reported to fail with desipramine<sup>18</sup> but achieve success with chlorpheniramine in Nigeria<sup>16</sup>. Furthermore, apart from the obvious elevated cost of treating malaria, many of these chemosensitizers have multisystemic effects, may elicit side effects and their various doses of chloroquine resistance reversal can be toxic<sup>19</sup>.

There are also strong indications that their use may be affected by behavioral factors in rural areas where herbal extracts are still used to treat febrile illnesses including malaria in these populations<sup>20</sup>.

This scenario has re-awakened interest in the exploration of medicinal plants from which antimalarials such as quinine and artemisinin were found<sup>21</sup>. For instance the recent work of Tona *et al*<sup>22</sup> provided a scientific validity for the traditional use of eight medicinal plants including *Vernonia amygdalina* for the treatment of malaria in the Democratic Republic of Congo.

*Vernonia amygdalina* is a perennial herb belonging to the *Compositae* family, extracts of the plant have been used in various folk medicines as a remedies against helminthic, protozoal and bacterial infections with subsequent scientific supports to these claims<sup>23</sup>. The findings of Tona *et al*<sup>21</sup>, Abosi and Raseroka<sup>24</sup> and Massaba<sup>25</sup> indicate that *Vernonia amygdalina* leaf extract holds promise as an antimalarial agent despite its inability to clear parasitaemia completely. In this regard, the possibility of vernonia enhancing the efficacy of chloroquine needs to

be explored.

In the context of Complementary and alternative medicine, we hypothesize that the outcome of this study would support or question the feasibility of developing cost effective and efficacious chloroquine-based antimalarial therapies with herbs especially in developing countries.

In the present study, various doses of aqueous vernonia leaf extract were combined with sub-curative and curative doses of chloroquine to investigate the effect of the plant on the prophylactic and chemotherapeutic efficacy of chloroquine in mice infected with chloroquine resistant and sensitive *Plasmodium berghei* strains.

The efficacy of *Vernonia amygdalina* as a chloroquine resistance reversal agent was also compared with that of chlorpheniramine.

## Materials and methods

### *Vernonia amygdalina* (*Compositae*)

Samples of *Vernonia amygdalina* plant were uprooted from the soil in a local farm situated less than 5 km from Lagos State University, Ojo, Nigeria and were taken to Forestry Research Institute, Ibadan Nigeria for authentication followed by deposition of the leaf as a herbarium collection with voucher number: FHI 106509.

The leaves, being detached from the plant stems and sieved to remove debris were then taken to the Pharmacognosy Department of College of Medicine, University of Lagos, where they were oven – dried at 50°C for 5 days and ground to powdery form prior to extraction.

### Plant extraction

500g of ground Vernonia leaves were stepped in sterile water (1500ml) at 26°C for 6 days under sterile conditions. On day 7, the concoction was filter sterilized by passage through a 45µm Millipore membrane filter (St Quentin, France). The filtrate was then freeze-dried under low pressure (Memmer, Ltd, Germany). The freeze dried sample was subsequently reconstituted with sterile phosphate buffered saline (PBS, pH 7.2) to 31.75 – 125mg/kg mouse body weight doses, designated as V31.75, V62.5 and V125 and stored in sterile bottles at 4°C until ready for use.

### Drugs

Tablets of chloroquine phosphate, CQ (Pfizer, Nigeria) and chlorpheniramine maleate, CP (Roche, Nigeria) were dissolved in PBS to final doses of 5mg/kg and 10mg/kg body weight for chloroquine (CQ) and 0.25mg/kg body weight for CP (CP 0.25).

## Animals

Inbred male and female (non-pregnant) Swiss albino mice weighing between 19 and 22g (mean weight, 20.4g) were obtained from the Animal House of College of Medicine, University of Lagos. The animals were observed under 12h light/dark cycle in metabolic cages in a well ventilated rodent cubicle. They were fed a mice pellet diet (Ladokun Farms, Nigeria) with water *ad libitum*. The caring and experimental use of the mice was in accordance with National Institute of Health Guidelines for Care of Laboratory animals [26]. The animals were acclimatized for 7 days prior to their randomization into the various experimental groups.

## Parasite

The two *Plasmodium berghei* clones used in this study were obtained from the Department of Biochemistry, Nigerian Institute of Medical Research, Lagos, Nigeria. The parasites are ANKA clones with chloroquine resistance (*P. berghei*<sup>R</sup>) and sensitive (*P. berghei*<sup>S</sup>) phenotypes and maintained by serial passage in mice with and without chloroquine pressure (5mg/kg).

## Parasite density determination and inoculum preparation

A standard inoculum was prepared from a donor mouse with *P. berghei* parasitized erythrocytes. Infected blood from the donor mouse was obtained by cardiac puncture after anesthesia with chloroform. Parasitaemia was established by microscopic examination of a thin blood film under oil immersion at x 1000 magnification and measured as a percentage of infected erythrocytes in fields of 500 erythrocytes. Each mouse was infected with a standard inoculum of the 10<sup>6</sup> parasitized erythrocyte suspension in phosphate buffered saline (0.2 ml) from a donor mouse that was prepared based on percentage parasitaemia and number of erythrocytes counted per microlitre of blood using an improved Neubear Haematocytometer.

## Prophylactic treatment

Here, a 4-day suppressive test according to Peter *et al* [27] was used. The animals were divided into 5 groups of 12 mice each. Animals in group 1 were given the vehicle only (i.e. 0.2ml PBS) and served as the uninfected control. Animals in group 2 were administered 5mg/kg suppressive dose of chloroquine and those in group 3 were further divided into three subgroups and administered vernonia extracts at 31.75, 62.5 and 125mg/kg doses. In group 4, the experimental animals were also divided into three subgroups and administered chloroquine in combination with the three selected do-

ses of vernonia extracts. Animals in group 5 (infected control) were also given the vehicle, but randomized into two subgroups before chloroquine resistant and sensitive parasite challenge.

Each mouse was intraperitoneally infected with 10<sup>6</sup> parasitized erythrocytes in 0.2 ml PBS suspension. Treatments commenced immediately after inoculation (Day 0) and continued on days 1, 2 and 3 via an oral route using a canula. Tail blood films of the infected animals were prepared, fixed in methanol, stained with 4% Giemsa stain for 20 min and examined microscopically under oil immersion on day 4 post inoculations. Haematocrit (PCV) reading for each animal was also taken after centrifugation of whole blood in sealed heparinized capillary tube [28] on the day of parasitaemia evaluation. Parasite density and percentage reduction in parasitaemia relative to chloroquine control on group-by-group basis were calculated.

## Curative treatment

In this experiment, another set of 60 albino mice randomized into 4 groups of 12 animals per group were intraperitoneally infected with 10<sup>6</sup> parasitized erythrocytes with oral treatments commencing on day 3 post inoculation. Animals in group 1 were given the vehicle only and served as the control. In group 2, the animals were given a curative dose (10mg/kg) of chloroquine daily for 3 days. Animals in group 3 were further divided into three subgroups and administered the selected 31.75mg/kg, 62.5mg/kg, and 125mg/kg doses of vernonia extracts. In group 4, the mice were also randomized into three subgroups and treated with chloroquine (10mg/kg) in combination with 31.75mg/kg, 62.5mg/kg, and 125mg/kg of vernonia extracts. Animals in Group 5 were treated with CQ (10mg/kg) in combination with 0.25 mg/kg of chlorpheniramine maleate. The chemosynthesizer was administered 12 hourly for seven days. Tail blood films were prepared starting from day 3 post inoculation on a daily basis till day 9 and thereafter every other day till day 28. Parasite clearance time (PCT) defined as time in hours to disappearance of peripheral parasitaemia in the infected mice following treatment and recrudescence time (RT) defined as time to reappearance of parasitaemia during the follow-up period were determined in all the treated groups. The number and percentage of survivors by days 14 and 28 were also recorded. Level of parasitaemia was also determined as previously described.

## Plasma preparation and toxicity testing.

Here, the animals were orally administered with 0.2ml PBS (control), 10mg/kg chloroquine, V31.75, V62.5,

V125, and 0.25.mg/kg CP every 24 hours for 7 days. On day 8, the animals were lightly anaesthetized with chloroform and subsequently sacrificed by cervical decapitation. Whole blood was collected into EDTA test tubes, mixed by rolling and then centrifuged at 5000 rpm for 5 min. The resulting plasma was subsequently employed for liver enzyme assays. The enzymes assayed for were glutamate – pyruvate (GPT) and glutamate – oxaloacetate (GOT) transaminases according to Bergmeyer and Bent <sup>[29]</sup> and lactate dehydrogenase as described by Wroblewski and La Due <sup>[30]</sup>.

### Statistical analysis

Data expressed as mean  $\pm$  SEM was analyzed for significance of disparity using a 2-way analysis of variance (ANOVA) and the F-distribution.  $P < 0.05$  was regarded as significant.

### Results

The data on day- 4 parasitaemia suppression by chloroquine (5mg/kg) and selected doses (31.75 – 125mg/kg) of *Vernonia amygdalina* leaf extracts is presented in Table 1. In the absence of prophylactic intervention, highest parasitaemia due to chloroquine sensitive ( $20.22 \pm 0.73$  %rbc) and resistant ( $21.40 \pm 0.22$  %rbc) *Plasmodium berghei* infection were observed in the infected control (Group 5). However, chloroquine elicited suppression of parasitaemia by 72.70% and 57.20% respectively in the animals infected with *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup>. The disparity in the resulting day 4 parasitaemia ( $5.52 \pm 1.19$  vs.  $9.16 \pm 0.9$  % rbc) was found to be significant ( $P < 0.05$ ). Prophylactic control of parasitaemia with the selected doses of *Vernonia amygdalina* extracts 31.25 – 125mg/kg) also revealed dose-dependent suppression of parasitaemia of comparable magnitude (32.10-79.37% vs. 35.65-80.71%) in *P.berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected mice when administered singly or in combination with chloroquine.

**Table 1. A 4-day suppressive test of aqueous leaf extracts of *Vernonia amygdalina* in *Plasmodium berghei* (ANKA) infected mice.**

Prophylactic experiment	<i>Plasmodium berghei</i> infection			
	<i>P. berghei</i> <sup>S</sup> . Parasitaemia (%rbc)	Suppression (%)	<i>P.berghei</i> <sup>R</sup> . Parasitaemia (%rbc)	Suppression (%)
Group 1 Uninfected (Control)	-	-	-	-
Group 2 CQ (5kg/kg)	$5.52 \pm 1.19$	72.70	$9.16 \pm 0.9^a$	57.20
Group 3				
V31.75	$13.73 \pm 1.30$	32.10	$13.77 \pm 1.52$	35.65
V62.5	$10.34 \pm 0.39$	48.86	$10.71 \pm 0.11$	49.95
V125	$7.93 \pm 0.29$	50.78	$7.99 \pm 0.32$	62.66
Group 4				
CQ5+V31.75	$8.67 \pm 0.22$	57.12	$9.12 \pm 0.64^a$	57.38
CQ5+V62.5	$6.83 \pm 0.42$	66.22	$6.87 \pm 0.23$	67.90
CQ5+V125	$4.17 \pm 0.21$	79.37	$4.13 \pm 0.10$	80.71
Group 5 <sup>†</sup> Infected Control	$20.22 \pm 0.73$	-	$21.40 \pm 0.22$	-

Data are expressed as mean  $\pm$  SEM of at least four mice per group or subgroup and analyzed by ANOVA

<sup>†</sup>The day 4 survival rates among the *P. berghei* infected control (Group 5) were 83.3 % (*P. berghei*<sup>S</sup>) and 75% (*P. berghei*<sup>R</sup>) respectively. CQ5 = Chloroquine at 5mg/kg dose; *Vernonia amygdalina* leaf extract given at doses of 31.75, 62.5 and 125 mg/kg are indicated as V31.75, V62.5 and V125 respectively. <sup>a</sup> $P < 0.05$  (*P. berghei*<sup>S</sup> vs. *P. berghei*<sup>R</sup>).  $P < 0.05$  was considered significant.

Prophylactic blood haematocrit level was found to reduce significantly ( $P < 0.05$ ) to 79.3 – 87% of uninfected control in infected animals treated with chloroquine, 31.75 – 125mg/kg extracts alone and combination with chloroquine at 31.75mg/kg dose (Figure 1).

The extracts were also tested for their ability to clear parasitaemia due to *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup>. Unlike

chloroquine at curative dose of 10mg/kg, which produced clearance time to  $4.8 \pm 0.2$  days and day 14 cure rate of 58.3% in mice with *P. berghei*<sup>S</sup> malaria, data indicate 100% failure rate (cure rate = 0%) when the extracts were used singly but dose-dependent cure rate of 66.7 – 100% when used in combination with chloroquine (Table 2).




Figure 1. Haematocrit level of mice infected with chloroquine resistant and sensitive strains of *Plasmodium berghei* (ANKA) in the 4-day suppressive assay of *Vernonia amygdalina* leaf extract. Data are presented as mean  $\pm$  SEM of at least 4 mice per group or subgroup and analyzed by ANOVA. Figures in parentheses represent % of uninfected control PCV values in *P. berghei* infected paired mice. <sup>a</sup>P < 0.05; <sup>b</sup>P < 0.01(Uninfected vs. infected mice).

Table 2. Response of *Plasmodium berghei* (ANKA) infection to treatment with chloroquine (30mg/kg) or *Vernonia amygdalina* extracts or chloroquine combined with selected doses of *Vernonia amygdalina* extracts in mice.

Curative experiment <sup>^</sup>	<i>Plasmodium berghei</i> infection					
	<i>P. berghei</i> <sup>S</sup>			<i>P. berghei</i> <sup>R</sup>		
	PCT $\pm$ SEM (days)	RT $\pm$ SEM (days)	Cure rate (%)	PCT $\pm$ SEM	RT $\pm$ SEM (days)	Cure rate (%)
Group 1						
Infected Control	-	-	0	-	-	0
Group 2						
CQ (10mg/kg)	4.8 $\pm$ 0.2 <sup>(12)a</sup>	7.2 $\pm$ 0.4 <sup>(5)a</sup>	58.3	-	-	0
Group 3						
V31.75	-	-	0	-	-	0
V62.5	-	-	-	-	-	0
V125	-	-	0	-	-	0
Group 4						
CQ10+V31.75	4.4 $\pm$ 0.3 <sup>(12)a</sup>	8.9 $\pm$ 0.2 <sup>(4)b</sup>	66.7	10.2 $\pm$ 0.2 <sup>(4)a*</sup>	3.2 $\pm$ 0.1 <sup>(4)a**</sup>	25
CQ10+V62.5	3.8 $\pm$ 0.4 <sup>(12)b</sup>	9.5 $\pm$ 0.3 <sup>(4)c</sup>	83.3	3.9 $\pm$ 0.4 <sup>(6)b</sup>	8.5 $\pm$ 0.5 <sup>(6)a**</sup>	50
CQ10+V125	2.6 $\pm$ 0.2 <sup>(12)c</sup>	18.9 $\pm$ 1.4 <sup>(2)d</sup>	100	2.8 $\pm$ 0.1 <sup>(8)c</sup>	19.5 $\pm$ 2.6 <sup>(2)c**</sup>	100
Group 5						
CQ10+CP0.25	2.8 $\pm$ 0.1 <sup>(12)c</sup>	-	100	2.8 $\pm$ 0.1 <sup>(8)c</sup>	19.8 $\pm$ 0.1 <sup>(2)c</sup>	100

Data are expressed as mean  $\pm$  SEM (n  $\geq$  2) and analyzed by ANOVA. <sup>^</sup>12 animals were allotted to each group or subgroup. -Percentage of animals with zero parasitaemia by day 14 post treatment. PCT = Parasite clearance time; RT = Recrudescence time. Figures in parentheses were number of animals in which parasite clearance and recrudescence were observed. Superscripts with different letters in each column connote significance (P < 0.05) between data. \*P < 0.05, \*\*P < 0.05 (*P. berghei*<sup>S</sup> vs. *P. berghei*<sup>R</sup> for PCT and RT respectively).

CQ10 = Chloroquine at 10mg/kg dose given daily for three days; *Vernonia amygdalina* leaf extract given at doses of 31.75, 62.5 and 125 mg/kg given daily for three days are indicated as V31.75, V62.5 and V125 respectively. CP0.25 = Chlorpheniramine at 0.25 mg/kg dose given 12 hourly for seven days. P < 0.05 was considered significant.

Chloroquine-chlorpheniramine combination also cleared parasitaemia (PCT = 2.8  $\pm$  .0.1 days) and elicited 100% cure rate by day 14 in both *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected malaria suggesting reversal of chloro-

quine resistance in the latter. However, the *P. berghei*<sup>R</sup> parasites recrudesced with recrudescence time of 19.8  $\pm$  0.1 days that was comparable to 18.9  $\pm$  1.4 and 19.5  $\pm$  2.6 days produced by chloroquine-V125 combination in *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected mice (Table 2).

The extracts were also tested for their ability to clear parasitaemia due to *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup>. Unlike chloroquine at curative dose of 10mg/kg, which produced clearance time to  $4.8 \pm 0.2$  days and day 14 cure rate of 58.3% in mice with *P. berghei*<sup>S</sup> malaria, data indicate 100% failure rate (cure rate = 0%) when the extracts were used singly but dose-dependent cure rate of 66.7 – 100% when used in combination with chloroquine (Table 2). Chloroquine-chlorpheniramine combination also cleared parasitaemia (PCT =  $2.8 \pm .0.1$  days) and elicited 100% cure rate by day 14 in both *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected malaria suggesting reversal of chloroquine resistance in the latter. However, the *P. berghei*<sup>R</sup> parasites recrudesced with recrudescence time of  $19.8 \pm 0.1$  days that was comparable to  $18.9 \pm 1.4$  and  $19.5 \pm 2.6$  days produced by chloroquine-V125 combination in *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected mice (Table 2).

Generally, parasite clearance time and recrudescence time were found to be reduced and prolonged significantly with increased doses of *Vernonia amygdalina* extracts in combination with chloroquine irrespective of the resistance status of the parasite (Table 2). The data presented in Table 3 shows dose-dependent percentage survival (16.7 -50%) in mice with *P. berghei*<sup>S</sup> malaria treated with the extracts alone by day 14 post treatment. By 28 post treatment, survivors (8.3 – 16.7%) were found only in the V125 treatment arm in both *P. berghei* infected groups. While treatment of the infected mice with chloroquine (10mg/kg) alone produced 6 (50%) survivors by day 28 only in the *P. berghei*<sup>S</sup>, combination treatment with selected doses of *Vernonia amygdalina* produced an improvement in survival rate in these animals with CQ-V62.5 and CQ-V125 eliciting highest survival rates of 66.7% each in the treated *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected mice (Table 3). Compared to the uninfected control, the *P. berghei*<sup>R</sup>-infected mice treated with a curative dose of chloroquine (10mg/kg) were also found to elicit a significant ( $P < 0.05$ ) decrease in haematocrit level (40.9 vs. 100%) but which improved with increased doses of the combinational *Vernonia amygdalina* extract achieving a non-significant level in the CQ-V125 treatment arm in both *P. berghei*<sup>S</sup> and *P. berghei*<sup>R</sup> infected mice groups (Figure 2). Table 4 shows the mean activity of sGPT, sGOT, and LDH in health mice administered via the oral route with the selected doses of *Vernonia amygdalina* leaf extracts alone or in combination with chloroquine (10mg/kg) for 7 days. Compared to the control (undrugged mice) with mean activity of  $32.4 \pm 2.4$  IU/L for sGPT,  $40.1 \pm 3.8$  IU/L for sGOT and  $114.2 \pm 8.7$  IU/L for LDH, chloroquine alone was observed to cause elevation in transaminase and LDH

activity by 13.4 – 23.6% and 5.6% respectively. A similar but dose-dependent increases in sGOT (3.0 – 33.8%), sGPT (8.5 – 20.1%) and LDH (2.7 – 11.7%) were further observed in mice drugged with the extract alone.

Vernonia –chloroquine combination drugging resulted in further elevation in these parameters with CQ + V125 combination eliciting increases greater than those of CQ + CP 0.25 (87.0 – 111.2 vs. 44.2 – 46.4%;  $P < 0.05$ ). However, no deaths of drugged and undrugged mice occurred by day 8 of analysis.

## Discussion

The increasing failure of antimalarials including chloroquine and sulphadoxine—pyrimethamine in many endemic sites of Africa has generated tremendous public health concern necessitating for more exploration of plants for newer antimalarial agents and optimization of those with existing antimalarial activity when used singly, as composite remedies or in combination with orthodox medicine<sup>31</sup>. The present study has not only validated the antiplasmodic activity of *Vernonia amygdalina* but has also demonstrated the inherent ability of the plant's aqueous leaf extract to work in favour of the restoration of chloroquine efficacy as a prophylactic and chemotherapeutic agent against chloroquine sensitive and resistant *P. berghei* infection in mice *in vivo*. This is because in the 4 – day suppressive assay, co-administration of vernonia with prophylactic dose of CQ resulted in the dose-dependent suppression of parasitaemia that was greater than the effects of chloroquine or selected doses of the plant extracts when used singly in *P. berghei*<sup>R</sup> infected mice. These combinations particularly CQ + V125 also suppress parasitaemia due to *P. berghei* with comparable prophylactic efficacy with chloroquine (5mg/kg) when used singly. The outcome with chloroquine was not unexpected since the parasite had a sensitive phenotype. A similar work by Okonkon *et al*<sup>32</sup> also revealed the efficacy of *Hippocrata africana* and *Uvaria chamae* but at larger doses of 200 – 900mg/kg, Garavito *et al*<sup>[33]</sup> had previously reported the alkaloid fraction of *Abuta grandifolia* to elicit 66% suppression of *P. berghei* parasitaemia at 250mg/kg. While in the work of Okpako and Ajaiyeoba<sup>34</sup>, the prophylactic functions of *Striga hemothica* and *Tapinanthus sessilifolius* extracts characterized by 51 – 68% suppression of *P. berghei* parasitaemia in mice was reported. Aside their high dose-anti-berghei efficacy, these plants were tested uncombined with chloroquine and also noted for toxicity<sup>[35]</sup>. Meanwhile, a few recent studies have reported antimalarial efficacy against *P. falciparum* and *P. berghei* of some singly applied plant extracts at microgram/kg doses<sup>19</sup>. But these observations

**Table 3. Survival of mice infected with *Plasmodium berghei* (ANKA) strain and treated with chloroquine (30mg/kg) or *Vernonia amygdalina* extracts or chloroquine combined with selected doses of *Vernonia amygdalina* extracts.**

Curative experiment	<i>Plasmodium berghei</i> infection			
	<i>P.berghei</i> <sup>S</sup> . Day 14 survivors n (%)	Day 28 survivors n (%)	<i>P.berghei</i> <sup>R</sup> . Day 14 survivors n (%)	Day 28 survivors n(%)
Group 1 Infected Control	0 (0)	0 (0)	0 (0)	0 (0)
Group 2 CQ (10mg/kg)	9 (75)	6 (50)	2 (16.7)	0 (0)
Group 3 V31.75	2 (16.7)	0 (0)	3 (25)	0 (0)
V62.5	5 (41.7)	0 (0)	4 (33.3)	0 (0)
V125	6 (50)	2 (16.7)	6 (50)	1 (8.3)
Group CQ10+V31.75	10 (83.3)	6 (50)	4 (33.3)	2 (16.7)
CQ10+V62.5	10 (83.3)	8 (66.7)	7 (58.3)	3 (25)
CQ10+V125	11 (91.7)	7 (58.3)	10 (91.7)	8 (66.7)
Group 5 CQ10+CP0.25	12 (100)	11 (91.7)	10 (83.3)	6 (50)

Data are number (%) survivors by days 14 and 28 among the infected mice treated with chloroquine or selected doses of *Vernonia amygdalina* leaf extracts (V) or chlorpheniramine (CP). CQ10 = Chloroquine at 10mg/kg dose given daily for three days; *Vernonia amygdalina* leaf extract given at doses of 31.75, 62.5 and 125 mg/kg given daily for three days are indicated as V31.75, V62.5 and V125 respectively. CP250 = Chlorpheniramine at 0.25 mg/kg dose given 12 hourly for seven days. The drug/extracts were administered orally as PBS suspension (0.2ml).




Figure 2. Haematocrit level of mice infected with *Plasmodium berghei* (ANKA) strains and treated with chloroquine or chloroquine in combination with selected doses of *Vernonia amygdalina* extracts. Data are presented as mean  $\pm$  SEM of at least 4 mice per group or subgroup and analyzed by ANOVA. Figures in parentheses represent % of uninfected control PCV values in *P.berghei* infected paired mice. <sup>a</sup>P < 0.05; <sup>b</sup>P < 0.01;(Uninfected vs. infected mice)

**Table 4. Toxicity testing of *Vernonia amygdalina* leaf extracts and chlorpheniramine in mice.**

#Drug group	sGPT	Biochemical parameter (IU/L)				
		(%)	sGOT	(%)	LDH (%)	
Control	32.8 ± 2.4	-	40.1 ± 3.8	-	114.2 ± 8.7	-
CQ (10mg/kg)	37.2 ± 3.1 <sup>a</sup>	13.4	49.6 ± 2.4 <sup>a</sup>	23.6	116.7 ± 10.3	2.2
V31.75	33.8 ± 2.4	3.0	43.5 ± 2.1	8.5	117.3 ± 13.2	2.7
V62.5	36.4 ± 2.4 <sup>a</sup>	11.0	47.8 ± 3.8 <sup>a</sup>	19.2	121.7 ± 3.1 <sup>a</sup>	6.6
V125	43.9 ± 4.2 <sup>b</sup>	33.8	48.2 ± 2.1 <sup>a</sup>	20.1	127.6 ± 4.2 <sup>a</sup>	11.7
CQ10+V31.75	47.5 ± 5.3 <sup>a</sup>	44.8	53.8 ± 7.2 <sup>a</sup>	34.2	138.5 ± 6.2 <sup>a</sup>	21.3
CQ10+V62.5	54.5 ± 3.5 <sup>c</sup>	66.2	59.4 ± 1.7 <sup>a</sup>	48.1	171.8 ± 5.3 <sup>b</sup>	50.4
CQ10+V125	68.2 ± 6.1 <sup>c</sup>	107.9	84.7 ± 5.2 <sup>b</sup>	111.2	213.6 ± 8.1 <sup>c</sup>	87.0
CQ10+CP0.25	47.3 ± 2.8 <sup>b</sup>	44.2	58.7 ± 3.1 <sup>a</sup>	46.4	165.3 ± 6.2 <sup>b</sup>	44.7

Data are expressed as mean ± SEM of five mice per group and analyzed using ANOVA.

<sup>#</sup>No deaths of the drugged and undrugged mice occurred by day 8. Different superscripted letters indicate significant difference ( $P < 0.05$ ) between data. % = Percentage increase in enzyme activity in international units (IU) per litre (L). <sup>abc</sup> $P < 0.05$ . sGOT = serum glutamate oxaloacetate transaminase; sGPT = Serum glutamate pyruvate transaminase; LDH = Lactate dehydrogenase.

were made *in vitro* based on parasite cultures, which are often influenced by culture medium and serum factors<sup>36</sup>.

However, in terms of orthodox medicine – plant extract combination, a few studies have also been reported. They include CQ-*Ekerbergia capensis* and CQ-*Clerodendrum myricoides* efficacy against multidrug resistant *P. falciparum* isolates<sup>37</sup> in culture, CQ-*Allium sativum* alone against *P. berghei* malaria<sup>38</sup> and *Azadiracta indica* with pyrimethamine against *P. yoelii nigeriensis* malaria in mice<sup>39</sup>. These combinations except *Azadiracta indica* - pyrimethamine at 800mg/kg<sup>[39]</sup> were found to lack prophylactic efficacy. A prophylactic study by Agbaje and Onabanjo<sup>40</sup> however revealed 96-hour protection against *P. yoelii* infection in mice by ethanolic extract of *Enantia chloranthia* at £ 150mg/kg. Therefore, our observation that *Vernonia amygdalina* at 125mg/kg in combination with CQ suppress parasitaemia by more than 70% on day 4 (96 h) connotes a stronger prophylactic action. Dose-dependent suppression of hematocrit reduction due to parasitaemia was also observed; indicating that of *Vernonia* may inhibit or compensate for erythrocyte destruction due to parasitaemia. Agomo *et al*<sup>41</sup> had previously reported an increased reticulocyte counts in *P. yoelii nigeriensis* infected mice treated with *Azadiracta indica*, *Morinda lucida* and *Enantia chloranthia* extracts to support this possibility. Moreso that greater improvement was observed in the therapeutic experiment.

That the efficacy of an antimalarial drug can be enhanced by combination with plant extracts has been found with *Azadiracta indica*-chloroquine combination at 800mg/kg<sup>39</sup> in *P. yoelii* malaria, *Tinospora cordifolia*-chloroquine combination in *P. falciparum* malaria via a daily 300mg dosing<sup>42</sup>, *E. capensis* and *C. myricoides* in combination with CQ with IC50 < 30 microgram/kg<sup>37</sup>

and *Khaya grandifolia*-CQ against *P. falciparum* with IC50 < 9.63microgram<sup>43</sup> (Bickii *et al*, 2000) and guanghuoxiang-sodium artesunate combination with IC50 < 100 microgram/kg<sup>44</sup>. It is of interest to know the higher therapeutic efficacy observed in some of these combinations are due to the active Phytoconstituents in the plant and not their crude preparations as tested in this study. For instance, limonoids and gedunin were responsible for the potency of *Khaya grandifolia* combination<sup>[43]</sup>. While it is the essential oil of guanghuaxiang that was tested in the combination with sodium artesunate<sup>[44]</sup>. While unlike the present study, *in vitro* culture assays were also used in these studies to monitor anti-plasmodial activity of the various combinations tested<sup>[37, 43, 44]</sup>.

Meanwhile, other anti-plasmodial phytoconstituents reported include quinoline alkaloids such as cephantharin, cryptolepine, isocryptolepine and neocryptolepine, coumarins and terpenoids<sup>[45, 46, 47, 48]</sup>. The last two Phytoconstituents are abundantly present in *Vernonia sp.* and may thus contribute to the observed anti-berghei properties of the plant.

However, the 62.5mg/kg and 125mg/kg combination doses at which *Vernonia* was found therapeutically effective in this study is relatively lower than effective doses reported by Nwafor *et al*<sup>[39]</sup> for *Azadiracta indica* (800mg/kg), and those previously reported for *Vernonia amygdalina* leaf extract<sup>[24, 25]</sup>. Plant extracts of *Bidens pilosa*, *Cochlospermum planchonii* have also been found to elicit antiplasmodial activity but with lower than 60% parasitaemia reduction profile at day 7 posttreatment<sup>[49, 50]</sup>. A randomized controlled trial study by Mueller *et al*<sup>[51]</sup> using *Artemisia annua* extract as antimalarial agent also revealed 74% cure rate for the plant but with high recrudescence rate thereby



withdrawing its recommendation as an alternative to modern antimalarials.

In this study, we observed *Vernonia* in combination with chloroquine to dose dependently prolonged recrudescence in < 50% of both the chloroquine sensitive and resistant *P.berghei* infected mice. This observation further reveals an anti-recrudescent potential of *Vernonia amygdalina* especially when administered at 125mg/kg dose. More so that these combinations also produced anti-berghei effects comparable to chlorpheniramine-CQ in terms of parasite clearance time (PCT) and recrudescence time (RT) particularly in the experimental chloroquine resistance *Plasmodium berghei* infection in the mice.

Chloroquine at therapeutic concentration in the parasite food vacuole, functions as a schizonticidal agent via arrest of DNA replication, inhibition of hemozoin formation and energy deprivation via interactions with parasite lactate dehydrogenase<sup>2, 53</sup> This chloroquine actions are prevented in resistance strains owing to parasite mediated alkalinisation and efflux of the drug from the food vacuole<sup>53</sup> but are restored by chemosensitizers such as chlorpheniramine as observed in this study. Therefore, the ability of *Vernonia amygdalina* leaf extract to elicit similar activity as chlorpheniramine is suggestive of the chemosensitizing (i.e. chloroquine resistance reversal) potential of the plant when used as an adjuvant with chloroquine. The action of *vernonia* may also involve prolongation of elimination half life chloroquine as reported for *Azadiracta indica*<sup>39</sup> or synergistic action with chloroquine in inhibiting hemozoin formation as reported for *Humulus lupulus*<sup>24, 25</sup>. Therefore, there is a need to advance the current status of *Vernonia amygdalina* to an antimalarial lead drug level through isolation and characterization active antiplasmodial components in the extracts, known to contain many terpenoid and alkaloid compounds.

The possibility of safety following the use of *vernonia* at combinational doses of 62.5 and 125mg/kg can be explained by the observed moderate – mild elevations in the plasma levels of liver enzymes in the experimental animals, which chlorpheniramine used presently in the management of uncomplicated malaria in Nigerian children<sup>[16]</sup> also elicited. *In vitro* cytotoxic effects of chlorpheniramine against human cell lines and cancer cells have been reported in a few studies<sup>55</sup>.

Taken together, the present study has demonstrated the potential of *vernonia* to reverse chloroquine resistance when used as an adjuvant with chloroquine to treat malaria. Further development of *Vernonia* for this purpose would no doubt provide cost

effective strategy of malaria control especially in developing countries where poor affordability and accessibility to orthodox drugs are the primary barriers to health care. Further studies involving the use of *Plasmodium falciparum* strains and their *in vitro* culture coupled with toxicity testing for the assessment of drug-extract efficacy and safety are being carried out.

### Acknowledgement

The technical assistance rendered by staff in the animal care unit of Nigeria Institute of Medical Research (NIMR), Lagos-Nigeria is sincerely appreciated.

### References

1. Klayman, DL. Weeding out malaria. *Natural History*. 1989; 10: 18 – 91
2. Luhan, M. Malaria. WHO Press Office fact sheet. 1996; 94: 1-3
3. Waller, D; Krishna, S; Crawley, J; Miller, R; Nosten, F; Chapman, D. Clinical features and outcome of severe malaria in Gambian children. *Clin Inf Dis*. 1995; 21: 557 – 587.
4. Sirima SB, Sawadogo R, Moran AC, Konate A, Diarra A, Yameogo M, Parise ME, Newman RD. Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupela District, Burkina Faso. *Clin Infect Dis*. 2003; 36(11):1374-82.
5. Binder, RK; Borrmann, S; Adegnika, AA; Missinou, MA; Kremsner, PG; Kun, JFJ. Polymorphisms in the parasite genes for pfcr1 and pfmdr-1 as molecular markers for chloroquine resistance in *Plasmodium falciparum* in Lambarene, Gabon. *Parasitol. Res*. 2002; 88: 475 – 476.
6. Trigg, IK; Mbwana, H; Chambo, O; Hills, E; Warkins, W; Curtis, CF. Resistance to pyrimethamine/sulfadoxine in *Plasmodium falciparum* in 12 villages in north East Tanzania and a test of chlorguanil/dapsone. *Acta. Trop*. 1997; 65: 155 – 189.
7. Wilson, CM; Volkman, SK; Thaitong, S; Martin, RK; Kyle, DS; Milhous, WK and Wirth, DF. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in *Plasmodium falciparum* in Thailand. *Biochem. Parasitol*. 1993; 57: 151-160
8. Skeetee, RW; Wirima, JJ; Slutsker, L; Khoromana, CO; Heyman, DL; Breman, JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with the use of chloroquine and mefloquine. *Am. J. Trop. Med. Hyg*. 1996; 55: 50-56
9. Price, RN; Nosten, F; Luxemburger, C; ter Kuile, FO; Paiphun, L; Chongsuphajaisiddhi, T. and White, NJ. Effects of artemisinin derivatives on malaria transmissibility. *Lancet*. 1996; 347: 1654 -1658
10. Olliaro, PL and Taylor, WRJ. Antimalaria compounds : from bench to bedside. *Exp. Biol*. 2003; 206: 3753 - 3759
11. Marsh, V. M., Mutemi, W. M., Muturi, J., Haaland, A., Watkins, W. M., Otieno, G. and Marsh, K. Changing home

- treatment of childhood fevers by training shop keepers in rural Kenya. *Trop. Med. Int. Health* 1999; 4: 383-389.
12. Mutabingwa, TK. Treating malaria during pregnancy in Africa. *Postgraduate Doctor Africa*. 2003; 25: 66- 73
  13. Martin, S.K; Oduola, AM and Milhous, WK. Reversal of chloroquine resistance in *Plasmodium falciparum* by verapamil. *Science*. 1987; 235: 899 – 901
  14. Donnelly, AV; Jason, CW; Petr, JS. Reversal of chloroquine resistance in *Plasmodium falciparum* using combinations of chemosensitizers. *Antimicrobial Agent. Chemother*. 2001; 45: 3171-3174
  15. Oduola, AMJ; Sowunmi, A; Milhous, WK; Brewer, TG; Kyle, DE; Gerena, L; Rossan, RL; Salako, LA; Schuster, BG. *In vitro* and *in vivo* reversal of chloroquine resistance of *P.falciparum* with promethazine. *Am. J. Trop. Med. Hyg.* 1998; 58: 625 - 629
  16. Sowunmi, A; Oduola, AMJ; Ogundahunsi, OAT; Falade, CO; Gbotosho, CO and Salako, A. enhanced efficacy of chloroquine-chlorpheniramine combination in acute uncomplicated falciparum malaria in children. *Trans. Roy. Of Trop. Med. & Hyg.* 1997; 91: 63-67
  17. Gerena, L; Bass, GT; Kyle, DE; Oduola, AMJ; Milhous, WK; Martin, RK. Fluoxetine hydrochloride enhances *in vitro* susceptibility of chloroquine in *Plasmodium falciparum*. *Antimicrob. Agents. Chemother*. 1992; 36: 2761-2765
  18. Warsama, M; Wernsdorfer, WH and Bjorkman, A. Lack of effect of desipramine on the response to chloroquine of patients with chloroquine-resistant falciparum malaria. *Transactions of the Royal society of Tropical Medicine and Hygiene*. 1992; 86: 235 – 236
  19. Crandall, I; Charuk, J and Kain, KC. Nonylphenoethoxylates as malarial chloroquine resistance reversal agents. *Antimicrob. Agents. Chemother*. 2000; 44: 2431 – 2434
  20. Farnsworth, NR and Soejarto, DD. Global importance of medicinal plants. In: Akerele, Heywood and singe (eds). Conservation of medicinal plants. London. Cambridge University Press. 1991; 25 – 51
  21. Basco, LK; Mitaku, S; Skaltsounis, A; Ravelomanantsoa, N; Tillenquin, F; Koch, Michel and Le Bras, J. *In vitro* activities of furoquinoline and acridone alkaloids against *Plasmodium falciparum*. *Antimicrobial Agents Chemother*. 1994; 38: 1169 - 1171
  22. Tona, L; Cimanga, RK; Mesia, K; Musuamba, CT; De Bruyne, T; Apers, S; Hernans, N; Van Miert, S; Pieters, L; Tottle, J; Vlietinck, AJ. *In vitro* antiplasmodic activity of extracts and fractions from seven medicinal plants used in the Democratic Republic of Congo. *J Ethnopharmacol*. 2004; 93: 27 – 32
  23. Tadesse A, Gebre-Hiwot A, Asres K, Djote M, Frommel D (1993). The *in vitro* activity of *Vernonia amygdalina* on *Leishmania aethiopica*. *Ethiop Med J*. 1993; 31: 183-189.
  24. Abosi AO, Raseroka BH. *In vivo* antimalarial activity of *Vernonia amygdalina*. *Br J Biomed Sci*. 2003; 60(2): 89-91.
  25. Masaba SC. The antimalarial activity of *Vernonia amygdalina* Del (Compositae). *Trans R Soc Trop Med Hyg*. 2000; 94: 694 - 695.
  26. Committee on Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. National Research Council. Washington. DC. DHEW Publ. No. (NIH) 1978; 78 - 123
  27. Peters, W. Drug resistance in malaria parasites of animals and human. *Adv. Parasitol*. 1998; 41: 1- 62.
  28. Dacie, JV and Lewis, SM (1991). In: Practical haematology. 7<sup>th</sup> edition. ELBS with Churchill Livingstone. Longman Group. UK. .Ltd.
  29. Bergemeyer, HU and Bent, E. Glutamatae – oxaloacetate transaminase, glutamate pyruvate transaminase. In Bergemeyer ed. Methods of Enzymatic Analysis. Academic Press New York, USA. 1963; Pp 837 - 852.
  30. Wroblewski, F and Ladue, JNS. Lactic dehydrogenase activity in blood. *Proc. Soc. Expt. Biol. Med*. 1955; 90: 210 – 213
  31. Bodeker G, Willcox M, GIFTS OF HEALTH, University of Oxford, United Kingdom. The first international meeting of the Research Initiative on Traditional Antimalarial Methods (RITAM). *J Altern Complement Med*. 2000; 6: 195-207
  32. Okokon JE, Ita BN, Udokpoh AE. The *in-vivo* antimalarial activities of *Uvaria chamae* and *Hippocratea Africana*. *Ann Trop Med Parasitol*. 2006; 100: 585-590
  33. Garavito G; Rincon J; Arteaga L; Hata Y; Bourdy G; Gimenez A; Pinzon R; Deharo E Antimalarial activity of some Colombian medicinal plants. *J Ethnopharmacol*. 2006; 107: 460-462.
  34. Okpako, LC and Ajaiyeoba, EO. *In vitro* and *in vivo* antimalarial studies of *Striga hermonthica* and *Tapinanthus sessilifolius* extracts. *Afr. J. Med. Med Sci*. 2004; 33: 73-75
  35. Ajaiyeoba EO; Abiodun OO; Falade MO; Ogbole NO; Ashidi JS; Happi CT; Akinboye DO. *In vitro* cytotoxicity studies of 20 plants used in Nigerian antimalarial ethnomedicine *Phytomedicine*. 2006; 13: 295-298.
  37. Muregi FW, Chhabra SC, Njagi EN, Lang'at-Thoruwa CC, Njue WM, Orago AS, Omar SA, Ndiege IO. Anti-plasmodial activity of some Kenyan medicinal plant extracts singly and in combination with chloroquine. *Phytother Res*. 2004 ; 18: 379-384
  38. Perez, HA; De La Rosa, M and Apitz, R. *In vivo* activity of ajoene against rodent malaria. *Antimicrobial Agents Chemother*. 1994; 38: 337 – 339
  39. Nwafor, SV; Akah, PA; Okoli, CO; Onyirioha, KC; Nwosu, CS. Interaction between chloroquine sulphate and aqueous extract of *Azadirachta indica*. A. Juss. (*Meliaceae*) in rabbits. *Acta. Pharm*. 2003; 53: 305 - 311
  40. Agbaje EO, Onabanjo AO. The effects of extracts of *Enantia chlorantha* in malaria. *Ann Trop Med Parasitol*. 1991; 85: 585-590
  41. Agomo, PU; Idigo, JC; Afolabi, BM. Antimalarial plants and their impact on cell populations in various organs in mice. *Afr. J. Med. Med Sci*. 1992; 21: 39 – 46.

42. Singh RK. *Tinospora cordifolia* as an adjuvant drug in the treatment of hyper-reactive malarious splenomegaly—case reports. *J Vector Borne Dis.* 2005;42:36-38
43. Bickii J,; Njifutie N; Foyere JA,; Basco LK,; Ringwald P. *In vitro* antimalarial activity of limonoids from *Khaya grandifoliola* C.D.C. Meliaceae). *J Ethnopharmacol.* 2000; 69:27-33.
44. Liu AR, Yu ZY, Lu LL, Sui ZY.; The synergistic action of guanghuoxiang volatile oil and sodium artesunate against *Plasmodium berghei* and reversal of SA-resistant *Plasmodium berghei*. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi.* 2000; 18: 76-78
45. Haruki, K; Bray, PG; Ono, M and Ward, SA. Potent enhancement of the sensitivity of *Plasmodium falciparum* to chloroquine by the bisphenyl-quinoline alkaloid cephantrin. *Antimicrob. Agents. Chemother.* 2000; 44: 2706 – 2708
46. Van Miert S; Hostyn S; Maes BU; Cimanga K; Brun R; Kaiser M; Matyus P; Dommissie R; Lemiere G; Vlietinck A; Pieters L. Isonocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound. *J Nat Prod.* 2005;68:674-677
47. Babalola OO, Anetor JI, Adeniyi FA. Amelioration of carbon tetrachloride-induced hepatotoxicity by terpenoid extract from leaves of *Vernonia amygdalina*. *Afr J Med Med Sci.* 2001; 30(1-2): 91-3.
48. Oketch-Rabah, HA; Lemmich, E; Dossaji, SF; Theander, TG; Olsen, CE; Cornett, C; Kharazmi, A; Christensen, SB. Two new antiprotozoal – 5- methylcoumarins from *Vernonia brachycalyx*. *J. Nat. Prod.* 1997; 660: 458 - 461
49. Oliveira FQ, Andrade-Neto V, Krettli AU, Brandao MG. New evidences of antimalarial activity of *Bidens pilosa* roots extract correlated with polyacetylene and flavonoids. *J Ethnopharmacol.* 2004 ; 93(1):39-42
50. Benoit-Vical F, Valentin A, Da B, Dakuyo Z, Descamps L, Mallie M. N'Dribala (*Cochlospermum planchonii*) versus chloroquine for treatment of uncomplicated *Plasmodium falciparum* malaria. *J Ethnopharmacol.* 2003; 89(1):111-4
51. Mueller MS, Runyambo N, Wagner I, Borrmann S, Dietz K, Heide L. Randomized controlled trial of a traditional preparation of *Artemisia annua* L. (Annual Wormwood) in the treatment of malaria. *Trans R Soc Trop Med Hyg.* 2004 ; 98(5):318-21
52. Krogstad, DJ; Gluzman, IV; Kyle, DE; Oduola, AMJ; Martins, SK; Millhous, WK and Schlesinger, PH. Efflux of chloroquine from *Plasmodium falciparum*: mechanism of chloroquine resistance. *Science.* 1987; 238: 1283-1285
53. Bray, PG; Mungthin, M; Riley, RG and Ward, SA. Access to hematin the basis of chloroquine resistance. *Mol. Pharmacol.* 1998; 54: 170-179
54. Frolich S; Schubert C; Bienzle U; Jenett-Siems K. *In vitro* antiplasmodial activity of prenylated chalcone derivatives of hops (*Humulus lupulus*) and their interaction with haemin. *J Antimicrob Chemother.* 2005;55:883-887
55. Medina, M A; Garcia de Veas R; Morata, P; Lozano, J; Sanchez-Jimenez, R. chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines. *Breast Cancer Res. Treat.* 1995; 35: 187 – 194